Nurix Q4 2020 Earnings Report
Key Takeaways
Nurix Therapeutics reported collaboration revenue of $6.7 million for the fourth quarter of 2020, with a net loss of $19.9 million, or $0.51 per share. The company's cash, cash equivalents, and investments totaled $372.0 million as of November 30, 2020.
First Investigational New Drug (IND) application cleared for NX-2127 in patients with relapsed and refractory B-cell malignancies
Three additional wholly owned programs expected to enter clinical trials in 2021
Expanded Sanofi collaboration resulting in option exercise payment of $22 million
Year-end cash and investments totaling $372 million
Nurix
Nurix
Nurix Revenue by Segment
Forward Guidance
Nurix anticipates commencing Phase 1 trials for NX-1607, NX-5948 and DeTIL-0255 in the second half of 2021 and dosing the first patient in a Phase 1a/1b trial for NX-2127 in the first quarter of 2021.
Positive Outlook
- Open IND and anticipates dosing the first patient in a Phase 1a/1b trial for NX-2127 in the first quarter of 2021.
- Anticipates commencing a Phase 1 trial for NX-1607 in the second half of 2021.
- Anticipates commencing a Phase 1 trial for NX-5948 in the second half of 2021.
- Anticipates commencing a Phase 1 trial for DeTIL-0255 in the second half of 2021